Literature DB >> 2981783

Herpes simplex virus type 2 and human papillomavirus type 16 in cervicitis, dysplasia and invasive cervical carcinoma.

S S Prakash, W C Reeves, G R Sisson, M Brenes, J Godoy, S Bacchetti, R C de Britton, W E Rawls.   

Abstract

Sera and biopsies of cervical lesions from 55 women with benign or malignant disease were analyzed for evidence of infection with herpes simplex virus type 2 (HSV-2) or human papillomavirus (HPV). In addition, information regarding known risk factors for cervical cancer was obtained by interview. The sera were tested for HSV-2 antibodies and the biopsies were tested for HPV or HSV DNA sequences by Southern blot hybridization. HSV-2 sequences were detected in 2/13 (15%) invasive neoplasms and in 1/12 (7%) benign lesions. Under non-stringent conditions of hybridization, reactions with HPV DNA were detected in biopsies of 2/17 (12%) inflammatory lesions, 6/12 (50%) intraepithelial neoplasms and 13/20 (65%) invasive neoplasms. All but one of the positive biopsies of invasive cancer, but only 4/11 biopsies of non-invasive lesions, contained HPV-16 DNA as determined by stringent hybridization conditions. Women with cervical cancer possessed the risk factors associated with the disease. Cigarette smoking and the presence of HPV-16 DNA were the most prominent risk factors. No evidence of an interaction between HSV-2 and HPV-16 was found among the cases of invasive cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981783     DOI: 10.1002/ijc.2910350109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Detection of DNA of human papillomavirus types 6/11 and 16/18 in cell scrapings of the uterine cervix by filter in situ hybridisation. Correlation with cytology, colposcopy and histology.

Authors:  T Demeter; J K Kulski; G F Sterrett; E C Pixley
Journal:  Eur J Epidemiol       Date:  1987-12       Impact factor: 8.082

Review 2.  The molecular biology of human papillomaviruses and the pathogenesis of genital papillomas and neoplasms.

Authors:  R S Ostrow; A J Faras
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

3.  Lymphotoxin production by regional lymph node lymphocytes in patients with uterine cervical cancer.

Authors:  K Matsunaga; H Mashiba; A Kurano; S Jimi
Journal:  J Clin Immunol       Date:  1990-09       Impact factor: 8.317

Review 4.  The interaction between human papillomavirus and other viruses.

Authors:  J T Guidry; R S Scott
Journal:  Virus Res       Date:  2016-11-05       Impact factor: 3.303

5.  Cancer of the cervix and the papilloma viruses.

Authors:  E G Knox; H S Shannon
Journal:  Eur J Epidemiol       Date:  1988-03       Impact factor: 8.082

6.  Human papillomavirus (HPV) type as an important determinant of the natural history of HPV infections in uterine cervix.

Authors:  K Syrjanen; S Parkkinen; R Mantyjarvi; M Vayrynen; S Syrjanen; H Holopainen; S Saarikoski; O Castren
Journal:  Eur J Epidemiol       Date:  1985-09       Impact factor: 8.082

7.  Human papillomavirus infection of the uterine cervix of women without cytological signs of neoplasia.

Authors:  P G Toon; J R Arrand; L P Wilson; D S Sharp
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-15

8.  Human papillomavirus (HPV) DNA sequences demonstrated by in situ DNA hybridization in serial paraffin-embedded cervical biopsies.

Authors:  S Syrjänen; K Syrjänen; R Mäntyjärvi; S Parkkinen; M Väyrynen; S Saarikoski; O Castren
Journal:  Arch Gynecol       Date:  1986

9.  Activation of human papillomavirus type 18 gene expression by herpes simplex virus type 1 viral transactivators and a phorbol ester.

Authors:  D Gius; L A Laimins
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

10.  Detection and typing of human papillomavirus infection affecting the cervix, vagina and vulva. Comparison of DNA hybridization with cytological, colposcopic and histological examinations.

Authors:  S Vuopala; R Pöllänen; A Kauppila; V P Lehto
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.